With an increase in the rate of survival of hematopoietic cell transplant (HCT) patients, the burden of late post-transplant complications also has increased tremendously. Unlike acute graft-versus-host-disease (GVHD), chronic GVHD and its complications may present in a variety of manifestations including scleroderma, fasciitis, polymyositis, myopathies, Sjögren's syndrome, neurological sequelae, primary biliary cirrhosis, vaginal GVHD, wasting syndrome, genital GVHD, bronchiolitis obliterans, immune cytopenias, and chronic immunodeficiency [1, 2]. From the functional quality of life point of view, the main aim of the management is to help improve overall function, joint range of motion, prevent contractures, aid the bone matrix, improve tissue-healing process, improve quality of life, and reduce pain. Currently, the main complimentary choice of therapy for managing musculoskeletal manifestation (MSK) of chronic GVHD seems to be largely focused on exercise therapy [3].